| Literature DB >> 27545681 |
Estelle Colin1, Jens Daniel2, Alban Ziegler1, Jamal Wakim3, Aurora Scrivo4, Tobias B Haack5, Salim Khiati3, Anne-Sophie Denommé1, Patrizia Amati-Bonneau1, Majida Charif3, Vincent Procaccio1, Pascal Reynier1, Kyrieckos A Aleck6, Lorenzo D Botto7, Claudia Lena Herper2, Charlotte Sophia Kaiser2, Rima Nabbout8, Sylvie N'Guyen9, José Antonio Mora-Lorca10, Birgit Assmann11, Stine Christ11, Thomas Meitinger12, Tim M Strom12, Holger Prokisch12, Antonio Miranda-Vizuete10, Georg F Hoffmann11, Guy Lenaers3, Pascale Bomont4, Eva Liebau2, Dominique Bonneau13.
Abstract
Via whole-exome sequencing, we identified rare autosomal-recessive variants in UBA5 in five children from four unrelated families affected with a similar pattern of severe intellectual deficiency, microcephaly, movement disorders, and/or early-onset intractable epilepsy. UBA5 encodes the E1-activating enzyme of ubiquitin-fold modifier 1 (UFM1), a recently identified ubiquitin-like protein. Biochemical studies of mutant UBA5 proteins and studies in fibroblasts from affected individuals revealed that UBA5 mutations impair the process of ufmylation, resulting in an abnormal endoplasmic reticulum structure. In Caenorhabditis elegans, knockout of uba-5 and of human orthologous genes in the UFM1 cascade alter cholinergic, but not glutamatergic, neurotransmission. In addition, uba5 silencing in zebrafish decreased motility while inducing abnormal movements suggestive of seizures. These clinical, biochemical, and experimental findings support our finding of UBA5 mutations as a pathophysiological cause for early-onset encephalopathies due to abnormal protein ufmylation.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27545681 PMCID: PMC5011045 DOI: 10.1016/j.ajhg.2016.06.030
Source DB: PubMed Journal: Am J Hum Genet ISSN: 0002-9297 Impact factor: 11.025